1. Chattipakorn N, Incharoen T, Kanlop N, Chattipakorn S. Heart rate variability in myocardial infarction and heart failure: review. Int J Cardiol 2007; 120: 289-96.
2. van Boven AJ, Jukema JW, Haaksma J, et al. Depressed heart rate variability is associated with events in patients with stable coronary artery disease and preserved left ventricular function. REGRESS Study Group. Am Heart J 1998; 135(4): 571-6.
3. Forslund L, Hjemdahl P, Held C, et al. Prognostic implications of ambulatory myocardial ischemia and arrhythmias and relations to ischemia on exercise in chronic stable angina pectoris (the Angina Prognosis Study in Stockholm). Am J Cardiol 1999; 84(10): 1151-7.
4. Forslund L, Hjemdahl P, Held C, et al. Prognostic implications of results from exercise testing in patients with chronic stable angina pectoris treated with metoprolol or verapamil. A report from the Angina Prognosis Study In Stockholm (APSIS). Eur Heart J 2000; 21(11): 901-10.
5. Ponikowski P, Anker SD, Chua TP, et al. Depressed heart rate variability as an independent predictor of death in chronic congestive heart failure secondary to ischemic or idiopathic dilated cardiomyopathy. Am J Cardiol 1997; 79(12): 1645-50.
6. Björkander I, Forslund L, Ericson M, et al. Long-term stability of heart rate variability in chronic stable angina pectoris, and the impact of an acute myocardial infarction. Clin Physiol Funct Imaging 2009; 29(3): 201-8.
7. Celik A, Ozturk A, Ozbek K, et al. Heart rate variability and turbulence to determine true coronary artery disease in patients with ST segment depression without angina during exercise stress testing. Clin Invest Med 2011; 34(6): E349.
8. Forslund L, Björkander I, Ericson M, et al. Prognostic implications of autonomic function assessed by analyses of catecholamines and heart rate variability in stable angina pectoris. Heart 2002; 87(5): 415-22.
9. Mortara A, LaRovere MT, Pinna GD, et al. Nonselective beta-adrenergic blocking agent, carvedilol, improves arterial baroflex gain and heart rate variability in patients with stable chronic heart failure. JACC 2000; 36(5): 1612-8.
10. Kubo T, Parker JD, Azevedo ER, et al. Vagal heart rate responses to chronic beta-blockade in human heart failure relate to cardiac norepinephrine spillover. Eur J Heart Fail 2005; 7(5): 878-81.
11. Zhang Q, Lu XN, Sun NL. Effects of Verapamil and Metoprolol on heart rate variability in patients with coronary heart disease. Beijing Da Xue Xue Bao 2007; 39(6): 610-3.
12. Tepliakov AT, Popov SV, Kaliuzhin VV, et al. Effects of carvedilol, atenolol and their combination with fosinopril on cardiac rhythm variability, clinico-functional status and quality of life in patients with postinfarction left ventricular dysfunction. Ter Arkh 2004; 76(9): 62-6. Russian (Тепляков А. Т., Попов С.В., Калюжин ВВ и др. Эффект карведилола, атенолола и их комбинации с фозиноприлом на вари- абельность сердечного ритма, клинико-функциональный статус и качество жизни пациентов с постинфарктной дисфункцией левого желудочка. Тер архив 2004; 76(9): 62-6).
13. Baevsky RM, Ivanov GG, Chireykin LV, et al. Analysis of heart rate variability using different electrocardiographic systems (Part 1). Herald arrhythmology 2002; 24: 65-86. Russian (Баевский Р. М., Иванов Г. Г., Чирейкин Л. В. и др. Анализ вариа- бельности сердечного ритма при использовании р азличных электрокардиогра- фических систем (часть 1). Вестник аритмологиии 2002; 24: 65-86). 14. Paschoal MA, Polessi EA, Simioni FC. Evaluation of heart rate variability in trained and sedentary climacteric women. Arq Bras Cardiol 2008; 90(2): 74-9.
14. Tarvainen MP, Laitinen TP, Lipponen JA, et al. Cardiac autonomic dysfunction in type 2 diabetes - effect of hyperglycemia and disease duration. Conf Proc IEEE Eng Med Biol Soc 2013; 2013: 5558-61.
15. Wennerblom B, Lurje L, Tygesen H, et al. Patients with uncomplicated coronary artery disease have reduced heart rate variability mainly affecting vagal tone. Heart 2000; 83(3): 290-4.
16. Takeyama J, Itoh H, Kato M, et al. Effects of physical training on the recovery of the autonomic nervous activity during exercise after coronary artery bypass grafting: effects of physical training after CABG. Jpn Circ J 2000; 64(11): 809-13.
17. Oliveira NL, Ribeiro F, Alves AJ, et al. Heart rate variability in myocardial infarction patients: effects of exercise training. Rev Port Cardiol 2013; 32(9): 687-700.
18. Routledge FS, Campbell TS, McFetridge-Durdle JA, Bacon SL. Improvements in heart rate variability with exercise therapy. Can J Cardiol 2010; 26(6): 303-12.
19. Novikova MV, Glezer MG. Trimetazidine therapy patients of different sexes with stable angina and electrocardiographically positive stress test. Problems of women’s health 2013; 8(3): 31-8. Russian (Новикова М. В., Глезер М. Г. Терапия триметазидином пациентов разного пола со стабильной стенокардией и электрокардиографиче- ски позитивным стресс-тестом. Проблемы женского здоровья 2013; 8(3): 31-8).
20. Glezer MG, Novikova MV. Antianginal and anti-ischemic efficacy of trimetazidine, depending on the age of the patients with stable angina. Clinical Gerontology 2013; 1-2: 27-34. Russian (Глезер М. Г., Новикова М. В. Антиангинальная и антиишеми- ческая эффективность триметазидина в зависимости от возраста пациентов со стабильной стенокардией. Клиническая геронтология 2013; 1-2: 27-34.
21. Novikova MV, Glezer MG. Effects of trimetazidine on parameters of ambulatory monitoring ECG and heart rate variability parameters. Cardiovascular Therapy and Prevention 2013; 12(5): 68-73. Russian (Новикова М.В., Глезер М.Г. Влияние триметазидина на показатели суточного мониторирования ЭКГ и параметры вариабельности ритма сердца. Кардиоваскулярная терапия и профилактика 2013; 12(5): 68-73).
22. Glezer MG, Astashkin EI, Novikova MV. Treatment of stable angina: state of the art. Farmateka 2013; 18: 31-8. Russian (Глезер М. Г., Асташкин Е.И., Новикова М.В. Лечение стабильной стенокардии: современное состояние вопроса. Фарматека 2013; 18: 31-8).
23. Ulgen MS, Akdemir O, Toprak N. The effects of trimetazidine on heart rate variability and signal-averaged electrocardiography in early period of acute myocardial infarction. Int J Cardiol 2001; 77(2-3): 255-62.
24. Guler N, Eryonucu B, Gunes A, et al. Effects of trimetazidine on submaximal exercise test in patients with acute myocardial infarction. Cardiovasc Drugs Ther 2003; 17(4): 371-4.
25. Birand A, Kudabierdieva GZ, Batyraliev TA, et al. Effects of trimetazidine on heart rate variability and left ventricular systolic performance in patients with coronary artery disease after percutaneous transluminal angioplasty. Angiology 1997; 48(5): 413-22.
26. Gunes Y, Guntekin U, Tuncer M, Sahin M. The effects of trimetazidine on heart rate variability in patients with heart failure. Arq Bras Cardiol 2009; 93(2): 154-8.
27. Zhou X1, Li C, Xu W, Chen J. Trimetazidine protects against smoking-induced left ventricular remodeling via attenuating oxidative stress, apoptosis, and inflammation. PLoS One 2012; 7(7): e40424.
28. Park KH, Park DW, Kim MK, et al. Effects of sheath injury and trimetazidine on endothelial dysfunction of radial artery after transradial catheterization. J Interv Cardiol 2012; 25(4): 411-7.
29. Di Napoli P, Chierchia S, Taccardi AA, et al. Trimetazidine improves post-ischemic recovery by preserving endothelial nitric oxide synthase expression in isolated working rat hearts. Nitric Oxide 2007; 16(2): 228-36.
30. Wu Q, Qi B, Liu Y, et al. Mechanisms underlying protective effects of trimetazidine on endothelial progenitor cells biological functions against H2O2-induced injury: involvement of antioxidation and Akt/eNOS signaling pathways. Eur J Pharmacol 2013; 707(1-3): 87-94.
31. Belardinelli R1, Lacalaprice F, Faccenda E, Volpe L. Trimetazidine potentiates the effects of exercise training in patients with ischemic cardiomyopathy referred for cardiac rehabilitation. Eur J Cardiovasc Prev Rehabil 2008; 15(5): 533-40.
